Secondary Logo

Journal Logo

Most Popular Articles

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports

Wang, Michael; Álvarez-Román, María Teresa; Chowdary, Pratima; More

Blood Coagulation & Fibrinolysis. 27(7):737-744, October 2016.

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

Lissitchkov, Toshko J.; Buevich, Evgeny; Kuliczkowski, Kazimierz; More

Blood Coagulation & Fibrinolysis. 28(2):152-162, March 2017.

Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products

Kogan, Alexander E.; Mukharyamova, Kadriya S.; Bereznikova, Anastasia V.; More

Blood Coagulation & Fibrinolysis. 27(5):542-550, July 2016.

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial

Lentz, Steven R.; Rangarajan, Savita; Karim, Faraizah A.; More

Blood Coagulation & Fibrinolysis. 28(3):224-229, April 2017.

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries

Bensadok, Meriem; Almomen, Abdulkareem; Alzoebie, Azzam; More

Blood Coagulation & Fibrinolysis. 28(2):145-151, March 2017.

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline: results of a multicenter management study

Aguilar, Carlos; Sartori, Michelangelo; D’Angelo, Armando; More

Blood Coagulation & Fibrinolysis. 29(6):562-566, September 2018.

Recombinant human prothrombin (MEDI8111) combined with fibrinogen dose-dependently improved survival time and reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding

Hansson, Kenny M.; Pehrsson, Susanne; Johansson, Karin J.; More

Blood Coagulation & Fibrinolysis. 30(4):140-148, June 2019.

Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study

Pernod, Gilles; Wu, Haifeng; de Maistre, Emmanuel; More

Blood Coagulation & Fibrinolysis. 28(3):254-260, April 2017.

Lack of grading agreement among international hemostasis external quality assessment programs

Olson, John D.; Jennings, Ian; Meijer, Piet; More

Blood Coagulation & Fibrinolysis. 29(1):111-119, January 2018.

Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications

Undas, Anetta; Zubkiewicz-Usnarska, Lidia; Helbig, Grzegorz; More

Blood Coagulation & Fibrinolysis. 26(6):621-627, September 2015.

Show: